LivaNova Board Appoints J. Christopher Barry as New Director
“The LivaNova Board of Directors is pleased to welcome Chris Barry,” said
With more than two decades of experience in the medical technology industry, Barry most recently served as the Chief Executive Officer and Director of NuVasive, Inc., from
“I am honored to join the LivaNova Board of Directors and look forward to supporting the efforts to bring life-changing improvements to patients around the world, while maximizing value to the shareholders,” said Barry.
With these changes, the LivaNova Board will be comprised of 10 Directors until Saia’s retirement at the end of the year.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the composition of the Board of Directors. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
LivaNova Investor Relations and Media Contacts
Director, Investor Relations
VP, Corporate Communications